Passage Bio appoints Dr. Michael Kamarck as Class I director

Passage BIO, Inc.

Dr. Kamarck appointed to board and Governance Committee, effective July 2, 2022.
He is Chairman of Sanofi Biotech Advisory Council and former CTO at Vir Biotechnology.
Received options to purchase 48,000 shares vesting over 36 months; cash per director policy.
Background includes ~30 years leadership at Merck, Wyeth, and Bayer.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Michael Kamarck

Class I director

PASG · Passage BIO, Inc.

Effective: 2022-07-02
Filed: July 6, 2022, 7:59 PM ET

appointed Dr. Michael Kamarck as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Michael Kamarck was appointed as Class I director at Passage BIO, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

appointed Dr. Michael Kamarck as a Class I director

View on SEC.gov

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-010548

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.